About Us

Where We JUST WEre

The synergies and successes of the first pediatric cancer dream team created a momentum that was too large to stop. The entire team wanted to continue to work together to push forward on the advances made in the first phase of the project. The St. Baldrick’s Foundation stepped forward to jointly fund the second phase of the Pediatric Cancer Dream Team. With funding from the St. Baldrick’s Foundation and the partner Institutions, the second phase of the Pediatric Cancer Dream Team involves 10 Institutions across the United States and Canada and includes oncologists, early career researchers, patient advocates, and many others.

This St. Baldrick’s – SU2C Pediatric Cancer Dream Team has treated over 1300 children on new immunotherapy clinical trials. The network has grown to include major new research initiatives under the umbrella of the Beau Biden Cancer Moonshot initiative within the Pediatric Immunotherapy Discovery and Development Network.

In April 2021, the PCDT was awarded the American Association for Cancer Research (AACR) Team Science Award, recognizing the significant contribution the PCDT has made to the pediatric cancer research community.

Where we are Going

In November 2022, the PCDT transformed into its third version, now renamed to EPICC: Empowering Pediatric Immunotherapies for Childhood Cancers. EPICC is funded by the St. Baldrick's Foundation.